Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.58 |
| ▸ | CTSD | P07339 | 3/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601744 | 0.93 | BACE1 (0.60) | BACE1CTSDCTSB | |
| SCHEMBL31462904 | 0.92 | BACE1 (0.59) | BACE1CTSD | |
| SCHEMBL30504227 | 0.92 | OPRM1 (0.62) | BACE1OPRM1OPRD1LTA4H | |
| SCHEMBL30052163 | 0.91 | CTSD (0.54) | BACE1CTSDOPRM1OPRD1LTA4H | |
| SCHEMBL30130747 | 0.91 | BACE1 (0.62) | BACE1CTSD | |
| SCHEMBL30538854 | 0.91 | OPRM1 (0.56) | BACE1OPRM1OPRD1 | |
| SCHEMBL10790323 | 0.90 | BACE1 (0.60) | BACE1CTSDLTA4H | |
| SCHEMBL29379268 | 0.90 | BACE1 (0.55) | BACE1CTSD | |
| SCHEMBL31612153 | 0.90 | BACE1 (0.55) | BACE1CTSD | |
| SCHEMBL28518726 | 0.90 | LTA4H (0.59) | BACE1CTSDOPRM1OPRD1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | BACE1 252/4885CTSD 503/4885OPRM1 804/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | BACE1 588/4885CTSD 213/4885OPRM1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.